AnaptysBio (ANAB) Expected to Announce Earnings on Wednesday

AnaptysBio (NASDAQ:ANAB) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect AnaptysBio to announce earnings of ($0.1252) per share and revenue of $17.3340 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The company had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $18.86 million. On average, analysts expect AnaptysBio to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

AnaptysBio Stock Performance

ANAB stock opened at $52.11 on Wednesday. AnaptysBio has a one year low of $11.40 and a one year high of $72.36. The firm’s fifty day moving average is $58.12 and its 200 day moving average is $57.69. The firm has a market cap of $1.54 billion, a PE ratio of -48.25 and a beta of 0.68.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Barclays increased their target price on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Piper Sandler reduced their price target on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Leerink Partners set a $90.00 price target on AnaptysBio in a research report on Friday, May 15th. Finally, Weiss Ratings lowered AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Institutional Trading of AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of ANAB. Smartleaf Asset Management LLC raised its position in shares of AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the last quarter. Larson Financial Group LLC boosted its holdings in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares in the last quarter. Osaic Holdings Inc. increased its stake in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of AnaptysBio by 987.3% during the fourth quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 1,560 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.